Burgos
Universidad
Hospital Universitario La Paz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (29)
2023
-
Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study
Neurologia, Vol. 38, Núm. 6, pp. 379-386
2022
-
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494
-
Epigenetic profiling linked to multisystem inflammatory syndrome in children (MIS-C): A multicenter, retrospective study
eClinicalMedicine, Vol. 50
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Epigenome-wide association study of COVID-19 severity with respiratory failure
EBioMedicine, Vol. 66
-
Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling
Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270
-
Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery
Clinical Therapeutics, Vol. 43, Núm. 5, pp. e86-e102
-
SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?
Journal of Experimental Medicine, Vol. 218, Núm. 6
2020
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Science, Vol. 370, Núm. 6515
-
Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects
Clinical Drug Investigation, Vol. 40, Núm. 7, pp. 617-628
-
Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates
Biomedicines, Vol. 8, Núm. 4
-
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Science, Vol. 370, Núm. 6515
2019
-
Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population
International Journal of Antimicrobial Agents, Vol. 54, Núm. 4, pp. 463-470
2018
-
Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects
Journal of Psychopharmacology, Vol. 32, Núm. 11, pp. 1212-1222
2017
-
Parkinson's disease severity at 3 years can be predicted from non-motor symptoms at baseline
Frontiers in Neurology, Vol. 8, Núm. OCT
-
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
Nature Genetics, Vol. 49, Núm. 9, pp. 1373-1384
2015
-
MAPT H1 haplotype is associated with late-onset Alzheimer's disease risk in APOE ε 4 noncarriers: Results from the dementia genetics Spanish consortium
Journal of Alzheimer's Disease, Vol. 49, Núm. 2, pp. 343-352
2014
-
Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia
Neurobiology of Aging, Vol. 35, Núm. 2, pp. 444.e1-444.e4
-
Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia
Human Molecular Genetics, Vol. 23, Núm. 3, pp. 749-754
2012
-
Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study
Movement Disorders, Vol. 27, Núm. 2, pp. 211-218